Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uPAR PET/CT Imaging in Neuroendocrine Tumors
NCT03278275Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Nov 2017
- Primary completion
- Jul 2021
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label trial of 68Ga-NOTA-AE105 in Neuroendocrine Neoplasm (NEN), sponsored by Rigshospitalet. Primary endpoint: uPAR PET/CT imaging of patients with neuroendocrine tumors at 1 hour. Started Nov 2017; status: completed.
02
Drugs
68Ga-NOTA-AE105
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03278275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278275.